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73. INTRODUCTION 
Prostate cancer is the most common cancer and the second leading cause of 
cancer mortality in males in industrialized countries (1). The disease is curable if 
detected early and when localized in the prostate. However, a large proportion 
of prostate cancers are diagnosed at clinically advanced stages (2). Prostate 
cancer can be detected at an early stage by determination of prostate-specific 
antigen (PSA) in serum and biopsy of men with elevated concentrations of PSA 
(3).
 PSA is a 33-kDa serine protease mainly produced by both normal and 
malignant prostatic epithelial cells (4-6). Serum PSA is the most important 
marker for diagnosis and monitoring of prostate cancer (3). However, the use of 
PSA in early detection of prostate cancer is problematic due to the high false-
positive rate caused by benign prostatic hyperplasia (BPH) (7, 8). About 5-35% of 
PSA in serum is in free form (9, 10); these forms comprise proPSA, enzymatically 
active PSA, and internally cleaved, enzymatically inactive PSA (11-13). Some 
studies have suggested that enzymatically active PSA and proPSA in serum are 
preferentially secreted by prostate cancer cells, and the cleaved forms are more 
specific to benign prostatic hyperplasia. Thus, determination of these PSA 
variants can reduce the number of false-positive results in early diagnosis of 
prostate cancer (14, 15).
 The main biological function of PSA is liquefaction of the seminal gel formed 
after ejaculation by proteolysis of semenogelins (16, 17). PSA has been proposed 
to inhibit prostate cancer growth and metastasis by proteolytic cleavage of 
plasminogen, generating angiostatin-like fragments (18-20). Angiostatin is an 
inhibitor of angiogenesis, a process necessary for tumor growth and metastasis. 
Thus, ligands binding to PSA and modulating its enzymatic activity are 
potentially useful for treatment of prostate cancer. 
 Phage display is a powerful approach for selection of novel ligands for 
various target molecules such as enzymes (21-23), antibodies (24), and receptors 
(25, 26). Phage peptide libraries offer a means of searching for ligands possessing 
unique binding specificities. 
84. REVIEW OF THE LITERATURE 
4.1. Prostate 
4.1.1. Anatomical Structure 
The human prostate is part of the male reproductive system and the accessory 
genital glands, along with the seminal vesicles and Cowper´s glands. Androgen 
action plays a central role in the physiological and pathological processes of the 
prostate (27, 28). The prostate of a normal adult male weighs 20 ± 6 g and is 
located immediately below the base of the bladder surrounding the proximal 
portion of the urethra (29, 30).
 The prostate can anatomically be divided into five lobes: anterior lobe, 
posterior lobe, median lobe, and two lateral lobes. A capsule of collagenous and 
elastic fibers and smooth muscle tissue encloses the prostate (31). For clinical 
purposes, the prostate is divided into three zones: the central zone, peripheral 
zone, and transition zone (Fig. 1) (31, 32). The peripheral zone is much larger 
than the central zone, and together they constitute ~95% of the prostatic 
glandular structure. The transition zone makes up ~5% of the glandular structure 
(32, 33), and it is the part of the prostate that is enlarged in prostatic hyperplasia 
(34). The peripheral zone is the most common site of prostate cancer (34).
4.1.2. Cell types (histological structure) 
The prostate contains fibromuscular (30%) and glandular (about 70%) 
components. Histologically, the ductal glands consist of epithelial cells 
surrounded by stromal tissue (31, 35).  The prostatic epithelium consists of three 
types of cells: columnar secretory epithelial cells, basal cells, and neuroendocrine 
cells (33, 35). The columnar secretory epithelial cells produce PSA, human 
kallikrein 2 (hK2), prostatic acid phosphatase (PAP), and other secreted proteins. 
Basal cells are important in the histological diagnosis of prostate cancer because 
prostate cancer acini lack basal cells. Neuroendocrine cells contain somatostatin, 
calcitonin, and other hormones scattered among secretory cells (36, 37).
 The stromal cells consist of fibroblasts, capillary and lymphatic endothelial 
cells, smooth muscle cells, neuroendocrine cells, and axons (35). Stromal cells 
serve as a matrix for the epithelium and contribute a variety of growth factors 
that regulate secretion, proliferation, differentiation, and apoptosis of epithelial 
cells (33, 38).
Fig. 1. Zones of the prostate. 
Reprinted from Walsh PC, Retik AB, Stamey TA, Vaughan DJ. Campbell´s Urology.
W.B. Saunders, Sixth ed, 1:344, 1992, with permission from Elsevier (Ref. 31).
4.1.3. Ejaculate and secretory proteins in seminal fluid 
The volume of normal human ejaculate ranges from 2 to 6 mL, the average 
volume being 3 mL (31). The ejaculate is composed of two main components, 
spermatozoa and seminal plasma. Spermatozoa account for less than 1% of the 
ejaculate volume. The prostatic fluid mixes with components from secretions of 
other male sex accessory glands to form seminal plasma. The major contribution 
originates from the seminal vesicles (1.5-2 mL), the prostate (0.5 mL), Cowper´s 
gland and the glands of Littre (0.1-0.2 mL) (39-42). The predominant prostatic 
secretory proteins are PSA, PAP, prostate-specific protein 94 (PSP94 or ??MSP)
and hK2. PSA is the most abundant protein secreted by the prostate (43-45).
4.2. Prostate-specific antigen (PSA) 
PSA was first purified from prostatic tissue and shown to be prostate-specific in 
1979 (4). One year later, it was demonstrated to be present in serum of patients 
with prostate cancer (46, 47).
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4.2.1. Expression of PSA 
PSA is produced by normal and malignant prostatic epithelial cells, and its 
expression is stimulated by androgens (48). PSA occurs at very high 
concentrations, ranging from 0.5-2 mg/mL, in human seminal plasma (49). PSA is 
quite organ-specific but it has been shown to be expressed at low concentrations 
in other human tissues and body fluids, e.g. in the periurethral glands, the anal 
gland, and breast tissue of males and females (50-53). PSA can occasionally be 
found in other cancer types, such as adrenal, kidney, lung, and colon cancers, 
and it has also been used as a prognostic marker for breast cancer (54-57). In 
ultrasensitive immunoassays, PSA can be detected at very low concentrations in 
female serum and other body fluids, including amniotic fluid, breast fluid, cyst 
fluid, and nipple aspirate fluid (58-60).
 In healthy men, PSA is mainly secreted into seminal fluid and only small 
amounts leak from the normal prostate into circulation; thus, serum 
concentrations are about one million-fold lower than those in seminal fluid (61).
In prostatic disease, the concentrations of serum PSA are elevated due to 
increased leakage of PSA into circulation (61).
4.2.2. Biochemistry and structure of PSA 
The human kallikreins (hK) are encoded by 15 structurally related genes (KLK) 
that colocalize to chromosome 19q13.4 (long arm of chromosome 19) (62-64). PSA 
is a chymotrypsin-like serine protease belonging to the human kallikrein family 
(62-64). It is encoded by a gene that is clustered within a 300-kb region on 
chromosome 19q13.4, together with hK2, tissue kallikrein (hK1), and 12 other 
recently characterized kallikrein genes (Table 1) (63-66). All members of the 
kallikrein family have five coding exons and display considerable sequence 
homologies (40-79%) at the DNA and amino acid levels. The best-known 
members are hK1, hK2, and PSA (hK3). PSA and hK2 are the most closely 
related, with 79% identity in amino acid sequence, while hK1 has 62% identity to 
PSA (67).
 The enzymatic activity of PSA is chymotrypsin-like but very restricted, and it 
preferentially hydrolyzes peptide bonds at the carboxy-terminus of the 
hydrophobic residues tyrosine and leucine (68). Several residues surrounding 
these preferred P1 residues play an important role in determining the substrate 
specificity (17, 69-71). Most studies on the enzymatic activity of PSA have 
utilized synthetic peptide substrates for chymotrypsin. Recently, peptide 
substrates based on the cleavage sites of PSA on semenogelines I and II have 
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been developed (17, 70, 72). Substrate phage display has also been used to study 
the enzymatic activity of PSA (71).
 PSA contains the catalytic triad characteristic of serine proteases. Residues 
His-41, Asp-96, and Ser-189 are located in typical sites of the active pocket (73,
74). Ser-183, which is located at the bottom of the active site, is crucial for the 
specificity of PSA (75).
Table 1. Members of the human Kallikrein family. 
Gene Protein (symbols) Protein (names) 
KLK1 hK1 tissue kallikrein 
KLK2 hK2 human kallikrein 2 
KLK3 hK3 prostate-specific antigen 
KLK4 hK4 prostase
KLK5 hK5 human kallikrein 5 
KLK6 hK6 protease M 
KLK7 hK7 human kallikrein 7 
KLK8 hK8 neuropsin
KLK9 hK9 human kallikrein 9 
KLK10 hK10 human kallikrein 10 
KLK11 hK11 human kallikrein 11 
KLK12 hK12 human kallikrein 12 
KLK13 hK13 human kallikrein 13 
KLK14 hK14 human kallikrein 14 
KLK15 hK15 prostinogen
 PSA is a single-chain glycoprotein. The structure deduced from the cDNA 
sequence shows that PSA is synthesized as a 261 amino acid (aa) prepropeptide 
comprising a 17-aa signal peptide, followed by a 7-aa propeptide and a 237-aa 
mature, enzymatically active protein (68, 76). The signal peptide is removed 
before secretion. ProPSA containing the activation peptide is enzymatically 
inactive and can be activated into the mature form by proteolytic cleavage with 
trypsin, hK2, hK4, and prostin (77-81). Activation with trypsin is the most 
efficient, followed by hK4 or prostin, and finally hK2 (77, 80-82). In seminal fluid, 
PSA occurs in the intact, enzymatically active form, but also in internally cleaved, 
inactive forms (nicked PSA) (83). The internal cleavage sites in the peptide 
backbone are at Arg-85, Lys-145 and Lys-182. They disrupt the conformation of 
PSA, causing loss of catalytic activity (62, 83-85).
 About 70% of PSA purified from seminal fluid is intact and enzymatically 
active, while 30% is nicked (83, 84). The average molecular weight (MW) of 
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native PSA determined by mass spectrometry is 28430 (86) and the relative 
molecular mass determined by SDS-PAGE or gel filtration is about 33 kDa (5, 49, 
86). The lymph node cancer of the prostate (LNCaP) cell line (87) mainly secretes 
PSA as an inactive proenzyme (82). Väisanen et al. found that about half of PSA 
consisted of a one-chain, mature, and enzymatically inactive form when LNCaP 
cells were grown in a medium containing fetal bovine serum (88). However, this 
one-chain mature PSA was enzymatically active when the LNCaP cells were 
grown in a medium without serum (88). The proenzyme form of PSA has also 
been produced as a recombinant protein (78, 89, 90). No proPSA has been 
detected in seminal fluid (91).
4.2.3. Biological function of PSA 
The main biological function of PSA is liquefaction of the seminal gel formed 
after ejaculation by proteolytic cleavage of semenogelin I and II, which are the 
major constituents of the seminal gel (16). Some studies have suggested that PSA 
plays a role in both inhibition or promotion of prostate cancer invasion and 
metastasis. PSA may inhibit cell growth and angiogenesis by generating 
angiostatin-like fragments from plasminogen (18-20), and it may also induce 
apoptosis (92). Other experiments suggest that PSA activates the urokinase-type 
plasminogen activator, which is thought to be involved in tumor invasion and 
metastasis (93), and affects tumor spread by proteolytic modulation of cell 
adhesion receptors (94). Furthermore, PSA has been found to cleave insulin-like 
growth factor binding protein 3 (IGFBP-3) and insulin-like growth factor binding 
protein 4 (IGFBP-4), causing release of active insulin-like growth factor 1 (IGF-I), 
which could enhance tumor growth (95, 96). PSA also cleaves fibronectin and 
laminin (97), and activates latent TGF-beta (94), and by these mechanisms it may 
mediate progression of prostate cancer.
4.2.4. Molecular forms of PSA in biological fluids 
In serum, the majority (50-90%) of the immunoreactive PSA consists of a complex 
with ?1-antichymotrypsin (PSA-ACT); minor parts occur in complex with other 
protease inhibitors, while about 5-35% of PSA is in free form (9, 10, 98).
 Free PSA in serum consists of different isoforms, mainly internally cleaved 
forms and proPSA (11, 99-101), but a small enzymatically active fraction has also 
been detected (13). ProPSA lacks enzymatic activity and does not form 
complexes with protease inhibitors (78, 88).  In addition, truncated forms of 
proPSA occur in serum from healthy men and patients with prostate cancer (15).
 A high proportion of nicked PSA has been found in BPH tissue and seminal 
plasma (102, 103). Serum from PCa and BPH patients also contains nicked PSA 
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(11, 101); the proportion of this form is in fact higher in BPH than in cancer (99,
100). Part of this PSA is internally cleaved after Lys-145 and Lys-182, and it is 
called BPSA (103, 104). Some assays detecting free PSA variants have been 
described. One assay uses a MAb that does not recognize PSA cleaved after Lys-
145 but binds to intact, mature PSA (105). Another assay that specifically detects 
internally cleaved PSA (after Lys-182) has recently been reported (104).
 Epithelial cells of the normal prostate secrete PSA into the prostatic glandular 
ducts. PSA reaches the circulation only by leaking backwards into the 
extracellular fluid and then diffusing into blood circulation (61).  However, when 
prostate cancer looses tissue architecture, polarization, and the connection to the 
prostatic ducts, PSA may be released directly into extracellular fluid and 
circulation in a more active form than when leaking out from BPH tissue (61, 98).
This could explain why the proportion of PSA occurring in complex with ACT is 
increased in prostate cancer serum. Niemelä et al. used an enzymatic assay to 
show that about 3% of PSA in serum from PCa patients occurs in an 
enzymatically active form (13). Noldus et al. analyzed free PSA from serum of 
PCa patients and found both intact (mature) and internally cleaved forms. The 
amino terminal sequence showed that the N-terminus is identical to that of free 
PSA from seminal fluid (100).
4.2.5. Clinical use of PSA
PSA was first detected in the serum of PCa patients In 1980, and after the 
pioneering studies of Stamey in 1987, measurement of serum PSA became a 
widely used marker for early detection, screening, and monitoring of PCa (3, 7).
PSA is not, however, a perfect tumor marker because PCa, BPH, and prostatitis 
can all cause increased serum PSA concentrations. Manipulation of the prostate, 
e.g. in cystoscopy and prostate biopsy, can also increase the concentrations of 
serum PSA. In apparently healthy men, the serum PSA level is below 4 µg/L in 
90%, 4-10 µg/L in 8%, and over 10 µg/L in 2% (106-108). A serum PSA below 4 
µg/L is traditionally considered to indicate a low risk for PCa. When serum PSA 
is in the range 4-10 µg/L, about 25-30% of these men have cancer detected by 
biopsy (7, 109). Men with serum PSA levels above 10 µg/L have a 40-50% 
likelihood of PCa (109).  However, PCa has also been detected in 20-30% of men 
with a PSA of 3-4 µg/L (107, 110, 111). The proportion of PSA-ACT is higher and 
that of free PSA is lower in serum of PCa patients than in BPH patients (2, 7, 9, 
10), and by assaying the proportion of either PSA-ACT or free PSA in relation to 
total PSA, about 20-30% of the false-positive results in BPH can be avoided (9). In 
spite of this, approximately two-thirds of the elevated results are still false-
positives (112). In addition, about 50% of men over 60 years of age have 
microscopic PCa. Thus, only 5-10% of the cancer is detected by PSA-based 
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screening (61, 98).
4.3. Prostate cancer
More than 95% of all prostate cancers are adenocarcinomas arising from the 
epithelium of the acini and terminal ducts. Most of the remainder are transitional 
cell carcinomas (31).
4.3.1. Diagnosis 
PCa is mainly located in the peripheral zone of prostate, with a small portion 
occuring in the central zone (34, 113). About 30-50% of men older than 50 years 
have a latent PCa, as assessed by postmortem autopsy (114).
 PCa is classified according to various grading systems. The Gleason grading 
system is widely used for pathological classification (115, 116). The TNM (tumor, 
node, metastasis) system is used to further classify the stage of cancer (117, 118).
 Usually, PCa causes clinical symptoms only when the cancer has spread to 
surrounding tissues or metastasized to lymph nodes or other organs of the body. 
Development of the serum PSA assay revolutionized the diagnosis and 
management of PCa. Diagnosis is currently based on the combined use of digital 
rectal examination (DRE), PSA assay, transrectal ultrasonography (TRUS), and 
transrectal ultrasound-guided biopsies (119, 120).
4.3.2. Treatment
Treatment strategies for PCa depend on the age and physical condition of the 
patient, the tumor stage, and the histopathological grade. If the cancer is 
localized and the general condition of the patient is good, radical prostatectomy 
or radiotherapy is the primary treatment (121-123). Alternatively, a watchful 
waiting is a viable option for some patients (2). In patients with local invasion, 
positive lymph nodes, or distant metastases, hormonal therapy is typically used. 
This approach slows tumor growth and reduces tumor volume but is not 
curative (124-126). Radiotherapy can also be used for local therapy of hormone-
resistant advanced disease. Recently, some novel therapeutic approaches, such as 
gene therapy (127), tumor-targeting with phage display peptides to selectively 
deliver cytotoxic drugs (128), and enzymatic activation of prodrugs (129), have 
been tested in experimental models.
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4.4. Benign prostatic hyperplasia (BPH) 
BPH is a very common disease in elderly men and affecting the same agegroup 
as PCa. The two diseases often co-exist. Pathophysiologically, enlarged 
hyperplastic nodules in the prostatic transition zone cause an increase in prostate 
volume. This compresses the prostatic urethra and elevates urethral pressure. 
However, prostatic size does not correlate with the degree of clinical symptoms. 
Options for treatment include transurethral resection (TURP), open surgery, and 
drug therapy.
4.5. Phage display methodology 
Phage display is a molecular diversity technology, which was first described by 
George Smith in 1985 (130). It presents a genetically well-defined system and has 
been applied to a broad spectrum of biological studies. Selection of peptides or 
proteins from phage display libraries is now an effective approach in searching 
for novel ligands for various target molecules. Phage display has recently been 
used in vivo for exploring peptides that home specifically to tumor blood vessels, 
lymphatic vessels, or cancer cells to develop targeted drug delivery tools for 
tumors (23, 131-134).
4.5.1. Biology and structure of bacteriophage 
Filamentous bacteriophage or phage comprise a large family of bacteriophage 
infecting different Gram-negative bacteria without lysing the host cells (135). The 
most widely applied phage are M13, fl, and fd. These infect Escherichia coli (E.
coli) male strains by attaching of the end of the phage (pIII) to the F pilus on the 
bacterial surface (sex pili encoded by the F episome) (136). Phage have a single-
stranded, covalently closed DNA genome, which is around 6400 nucleotides long 
and comprises 11 genes (Fig. 2) (137). The single-stranded DNA (ssDNA) is 
extruded through the membrane and is covered by capsid proteins. Bacterial 
enzymes synthesize the complementary strand and convert the infecting phage 
DNA into a supercoiled, double-stranded replicative form (RF) (137). This RF 
undergoes rolling circle replication to create a single-stranded DNA and also 
serves as a template for the synthesis of phage proteins (138).
 Phage particles are about 6-7 nm wide, 900-2000 nm long, and have a mass of 
approximately 16.3 MDa (Fig. 3) (137, 139). Three of the 11 genes in phage are 
required for DNA synthesis (products of genes II, V, and X) (Table 2), and five 
are virion structural proteins (those encoded by genes III, VI, VII, VIII, and IX). 
Two genes (I and IV) are involved in phage morphogenesis (137, 140). The 
products of structural genes VII and IX (pVII and pIX) are incorporated at the 
end of the virion that is extruded first (C-terminal end) and gene V proteins (pV) 
are removed from the DNA and shed back into the cytoplasm, being replaced by 
molecules of the major coat protein (pVIII).  The products of genes III and VI
(pIII and pVI) are incorporated at the other end (N-terminal) of the viral particle, 
and the assembled phage is released into the medium (136, 137).
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Fig. 2. Genome of the f1 bacteriophage. 
The single-stranded DNA contains 11 
genes and has 6407 nucleotides, which
are numbered from the unique HindII site 
located in gene II (represented by 0). IG, 
intergenic region; PS, packaging signal;
(+/-), the position of the origin of
replication of the viral and 
complementary DNA strands; arrows 
indicate the location of the overlapping 
genes X and XI. Reprinted from Kay BK, 
Winter J, McCafferty J. Phage Display of 
Peptides and Proteins. A Laboratory Manual, 5, Academic Press, 1996, with permission 
from Elsevier (Ref. 137). 
Fig. 3. The Ff bacteriophage particle. 
Schematic representation of the phage particle showing location of the capsid proteins
and orientation of the DNA. Reprinted from Kay BK, Winter J, McCafferty J. Phage
Display of Peptides and Proteins. A Laboratory Manual, 9, Academic Press, 1996, with 
permission from Elsevier (Ref. 137). 
There are two important coat proteins on the phage. The major coat protein is 
pVIII, a 50-aa residue protein of which the phage expresses about 2700 copies. 
The gene III protein (pIII) contains 406 amino acids and expresses 3-5 copies on 
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each phage (140).
Table 2. Genes and gene products of f1 bacteriophage. 
Gene No. of
amino acids 
MW Function Function
group
I 348 39,502 Assembly 3
II 410 46,137 DNA replication 1
III 406 42,522 Minor capsid protein 2
IV 405 43,476 Assembly 3
V   87   9,682 Binding ssDNA 1
VI 112 12,342 Minor capsid protein 2
VII   33   3,599 Minor capsid protein 2
VIII   50   5,235 Major capsid protein 2
IX   32   3,650 Minor capsid protein 2
X 111 12,672 DNA replication 1
XI 108 12,424 Assembly 3
Gene function group 1 encodes proteins required for DNA replication; gene function 
group 2 encodes proteins which make up the capsid of the phage; gene function group 3 
encodes proteins involved in the membrane-associated assembly of the phage. MW, 
molecular weight. Adapted from Kay BK, Winter J, McCafferty J. Phage Display of 
Peptides and Proteins. A Laboratory Manual, Academic Press, 1996 (Ref. 137). 
4.5.2. Principles and applications of phage display 
Phage display is an effective method for selection of novel ligands for target 
molecules. Foreign peptides or proteins are displayed on the surface of the 
phage by inserting the displayed genes (DNA fragments or synthetic 
oligonucleotides) between the signal peptide and the structural gene of the gene 
coding for the major (pVIII) or minor (pIII) coat proteins (Fig. 3).  This facilitates 
linking the phenotype of the phage to its genotype (130).
 Peptides displayed on pVIII have the benefit of more of their copies being 
displayed per phage (about 2700 copies), but the length of the inserts is restricted 
to 6-8 amino acids (141). Inserts fused to pIII can code for peptides longer than 
those fused to pVIII, and inserts comprising up to 15 amino acids do not disturb 
the function of the phage coat proteins (142, 143). To display larger size peptides 
or proteins, construction of hybrid viral vectors are needed (144).
 The key steps of applying phage display are as follows (145-148) (Fig. 4):
1) DNA technology is used to build phage display libraries. Fragments of DNA 
or synthetic oligonucleotides encoding the proteins or peptides are inserted at an 
engineered restriction site in phage gene III or VIII. 
2) The libraries are screened with target molecules of interest to select specific 
phage-displayed peptides or proteins. This step is termed “biopanning”. 
3) The phage bound to target molecules can be eluted and amplified by infecting 
the bacteria with phage and again selecting for binding to the same target 
molecule.
4) Sequences of the selected peptides or proteins can be deduced by DNA 
sequencing of selected individual phage clones released from bacterial host cells.
Inserting displayed gene in phage gene III or VIII
Screening phage library with target molecule
Removing nonspecific phage by washing
Amplifying eluted phage
Determining the sequence of selected phage
Fig. 4. Illustration of the phage display technology.
Adopted from Koivunen E, Restel BH, Rajotte D, Lahdenranta J,
Hagedorn M, Arap W, et al. Integrin-binding peptides derived from
phage display libraries. Methods Mol Biol 1999;129:3-17 (Ref. 148).
Eluting specifically bound phage
Target
molecule
Target
molecule
Target
molecule
Target
molecule
The main applications of phage display are as follows:
1) To display natural peptides or proteins for mapping epitopes of antibodies (24,
149).
2) To display synthetic random peptides and proteins to search for novel ligands 
for target molecules (25, 71, 150).
3) To display synthetic random peptides to identify ligands that home 
specifically to tumor blood vessels, lymphatic vessels, and cancer tissues in order 
to develop targeted therapy (23, 128, 131, 134).
4) To display proteins for evolution and improvement of protein function (151).
5) To generate potent and novel antibodies (152).
4.6. Nuclear magnetic resonance (NMR) technology
Nuclear magnetic resonance (NMR) is a powerful technology for analyzing the 
structure and dynamics of molecules. It can provide structural information on 
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molecules at atomic resolution and as well as information on dynamics, 
conformational equilibria, folding, and intra- and intermolecular interactions 
(153, 154). NMR experiments are performed on a NMR spectrometer consisting 
of two main components: a high field superconductive magnet that produces an 
extremely homogeneous, strong static magnetic field and a console that can 
record signals from the sample and generate electromagnetic waves in any 
desired combination (155).
 The basis of NMR experiments is a quantum mechanical property of the 
nucleus, the spin. Usually, the nuclei of interest carry a spin of 1/2 that allows 
only two different spin states; these are often referred to as “spin up” and “spin 
down”. Associated with the spin is a magnetic moment, which can be interpreted 
as a magnetic dipole (153).
 Hydrogen nuclei (protons) are the most sensitive type of nuclei. Analysis of 
biological molecules starts with large proton magnetization and transfer of the 
signal via heteronuclei (e.g. carbon or nitrogen) back to protons to record the 
NMR signal (free induction decay) with maximal sensitivity. The proton offers 
the best sensitivity, hence constituting the preferred nucleus for detection of the 
NMR signal.
 In NMR experiments, each tested nucleus produces an individual signal 
(resonance line) in the spectrum, and spectra of a biological molecule contain 
hundreds or even thousands of resonance lines. By using conventional 1-D NMR, 
it is not possible to analyze biological molecules due to the vast number of 
resonance lines. The foundation of structural NMR studies is a high-quality 
NMR spectra recorded with good sensitivity and spectral resolution. 
Multidimensional NMR spectra provide both increased resolution and 
correlations that are easy to analyze. Nowadays, NMR experiments with 
biological molecules are often measured in two or three dimensions. However, 
molecular structures larger than 30 kDa are hard to study by NMR (156, 157).
 NMR measurements are usually carried out in solution under near-
physiological conditions. The key steps of NMR structure determination are as 
follows:
1) Preparation of the protein solution. 
2) NMR measurements. 
3) Assignment of NMR signals to individual atoms in the molecule. 
4) Identification of conformational constraints. 
5) Calculation of the 3-D structure based on the basis of the constraints, which 
are determined from experimental results.
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5. AIMS OF THE STUDY 
The purpose of this study was to utilize phage display to identify novel PSA-
binding peptides and to use these as tools for developing new diagnostic 
methods for prostate cancer. 
 Specific aims were as follows: 
1) To identify novel binding ligands for PSA using phage display.
2) To use PSA-binding peptides for isolation of enzymatically active PSA. 
3) To use PSA-binding peptides as agents for developing new diagnostic assays 
for determination of enzymatically active forms of PSA in circulation. 
4) To characterize the peptide structures required for binding to PSA. 
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CA, USA). 
6.4. Production of PSA-binding peptides as GST fusion proteins 
Single-stranded phage DNA was purified and the insert region was amplified by 
PCR (160). The amplified DNA was isolated and subcloned between the BamHI
and EcoRI sites of the PGEX-2TK vector (Amersham Pharmacia Biotech, Finland). 
Recombinants were verified by DNA sequencing. The glutathione S-transferase 
(GST) fusion proteins were expressed in E. coli BL 21 cells and purified by 
glutathione affinity chromatography (Amersham Pharmacia Biotech) as 
described elsewhere (161). Peptides were released from the GST fusion partner 
by thrombin cleavage (162).
6.5. Synthesis of PSA-binding peptides and its derivatives 
PSA-binding peptides and various derivatives were chemically synthesized on 
the PerSeptive 9050 Plus peptide synthesizer using Fmoc strategy with 
TBTU/DIPEA as the coupling reagent and NovaSyn TGA with 4-
hydroxymethylphenoxyacetic acid linker as the solid phase (Novabiochem, 
Läufelfingen, Switzerland). Side-chain protecting groups were used during 
synthesis. Acetamidomethyl (Acm) was used to facilitate cyclization in the side-
chains of Cys(1) in peptide B-2 and Cys(5) and Cys(10) in peptide C-4.
 For coupling to CH-Sepharose, the peptides were modified by adding a 
spacer sequence of alternating Lys and Ser residues connected to the amino 
terminus of the peptide via an amino caproic acid (aca) bridge. The structure of 
the peptides with the spacer was SKSKSKS-aca-CVFAHNYDYLVC (B-2) and 
SKSKSKS-aca-CVAYCIEHHCWTC (C-4). Peptides with cysteines (Acm) were 
cyclized by using the Iodine method (163).
 Alanine replacement sets and other modified peptides were synthesized with 
the Apex 396 DC multiple peptide synthesizer (Advanced ChemTech, Louisville, 
KY, USA). In alanine replacement sets, all amino acids except cysteines were 
replaced one by one. The same synthesis method and amino acids were used as 
described above. 
6.6. Immunoassays 
6.6.1. Time-resolved immunofluorometric assays (IFMAs) 
A monoclonal antibody (MAb) was coated onto microtitration wells and the 
antibodies used as tracers were labeled with an europium (Eu3+) chelate (164). In 
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the assays, 25 µL of standard or sample and 200 µL of assay buffer [50 mM Tris-
HCl, pH 7.7, 150 mM NaCl, 33.3 µM bovine serum albumin (BSA), 1 µM bovine 
globulin] were added to the wells. For assaying chromatographic fractions, a 
sample volume of 200 µL (together with 25 µL of IFMA assay buffer with a 10-
fold BSA concentration) was used. After incubation, the wells were washed 
(washing buffer: 150 mM NaCl, 7.7 mM NaN3, 0.2 g/L Tween 20) and filled with 
200 µL of assay buffer containing Eu3+-labeled antibody. After incubation and 
washing, 200 µL of enhancement solution (PerkinElmer Life Science, Wallac, 
Finland) was added, and the fluorescence was measured with a Victor 1420 
multilabel counter (Perkin-Elmer Life Science, Wallac). 
6.6.2. Phage IFMA
The binding of individual phage clones to PSA was tested by phage IFMA. PSA 
was added to MAb 5E4-coated wells for 1 h. After washing, individual phage 
clone in 200 µL of assay buffer was added. After incubation for 1 h, the wells 
were washed and filled with 200 µL of assay buffer containing 50 ng of Eu3+-
labeled anti-phage monoclonal antibody (P. Saviranta, University of Turku, 
Finland). After further incubation for 60 min, the wells were washed four times, 
enhancement solution was added, and fluorescence was measured. 
6.6.3. Immunopeptidometric assay (IPMA) 
PSA purified from seminal fluid, serum samples or proPSA before and after 
activation with trypsin were used to study the reactivity of PSA-binding peptides 
in the IPMA. Twenty-five microliters of samples or calibrators (enzymatically 
active PSA) and 200 µL of assay buffer were added to MAb 5E4-coated wells and 
incubated for 1 h. After incubation, the wells were washed and 1 µg of GST-
peptide and 200 µL of assay buffer were added. After incubation for 60 min, the 
wells were washed and 50 ng of Eu3+-labeled anti-GST antibody (Amersham 
Pharmacia Biotech) and 200 µL of assay buffer were added and incubation was 
continued for 60 min. The wells were washed four times, enhancement solution 
was added, and after 5 min the fluorescence was measured.
6.7. Measurement of enzymatic activity 
6.7.1. Effect of peptides on the enzymatic activity of PSA
The effect of peptides on the enzymatic activity of PSA was assayed in the 
absence or presence of Zn2+ by using the chromogenic substrate S-2586 
(Chromogenix, Mölndal, Sweden). PSA was incubated with a 1- to 100-fold 
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molar excess of GST-peptide fusion proteins in Tris-buffered saline (TBS) 
containing 0.5 g/L BSA for 1 h at 22oC. After addition of substrate to a final 
concentration of 0.2 mmol/L, the absorbance was monitored at 5-min intervals at 
405 nm. The effect of the peptides on the enzymatic activity of other proteinases 
was also tested using the substrate S-2586 for chymotrypsin and cathepsin G, and 
S-2222 (Chromogenix) for trypsin (165).
6.7.2. Determination of proPSA activation
Purified proPSA was incubated in a MAb 5E4-coated well with slow shaking for 
1 h at 22oC. After washing two times, bound proPSA was activated by addition 
of bovine trypsin (Sigma Chemical, St. Louis MO, USA) (2 nmol/L) in 200 µL 
buffer (0.5% BSA/TBS) and incubated for 20 min at 22oC. After washing, a 
fluorescent peptide substrate (Enzyme Systems Products, Livermore, CA, USA) 
was added to a final concentration of 400 µmol/L, and fluorescence (excitation 
wavelength at 355 and emission wavelength at 460 nm) was monitored for 120 
min in a Victor1420 multilabel counter (Perkin-Elmer Life Science) (13).
6.8. Chromatographic methods 
6.8.1. Purification of PSA 
Seminal plasma was precipitated with ammonium sulfate at 25% and 70% 
saturation. After dialyzing the precipitate at 70% saturation against 50 mmol/L 
Tris buffer, it was applied to an immunoaffinity column containing MAb 5E4. 
The column was washed and PSA was eluted with 0.1% trifluoroacetic acid. PSA 
isoenzymes were further separated by anion exchange chromatography on a 
Resource Q column (Amersham Pharmacia Biotech). 
 ProPSA was purified from the LNCaP cell culture medium using an 
immunoaffinity column with PSA-MAb 4G10, followed by cation exchange 
chromatography on a Resource S column (Amersham Pharmacia Biotech). The 
purified proPSA was activated by treatment with bovine trypsin (Sigma) as 
described (77).
6.8.2. Ion exchange chromatography
The isoenzymes (A-E) of PSA were further separated on a Resource Q column 
(Amersham Pharmacia Biotech). Immunoaffinity-purified PSA was dialyzed 
against 10 mmol/L Tris-HCl buffer, pH 8.7 (buffer A), and applied to the 
Resource Q column. PSA isoenzymes were eluted with a linear gradient (0-100%) 
of buffer A and buffer B (buffer A containing 0.3 mol/L NaCl). For purification of 
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proPSA, immunoaffinity-purified LNCaP-PSA was dialyzed against 50 mmol/L 
phosphate buffer, pH 5.6 (buffer A), and applied to a Resource S column 
(Amersham Pharmacia Biotech). ProPSA was eluted with a linear gradient (0-
100%) of buffer A and buffer B (buffer A containing 0.5 mol/L NaCl).
6.8.3. Gel filtration 
Gel filtration was performed on a Superdex-200 HR 10/30 column or a 1.6x60 cm 
Superdex-200 column (Amersham Pharmacia Biotech) using 50 mmol/L sodium 
phosphate buffer, pH 7.4, containing 150 mmol/L NaCl and a flow rate of 15 or 
30 mL/h. The column was calibrated using IgG (160 kDa) and BSA (67 kDa) as 
molecular size markers. 
6.8.4. Immunoaffinity chromatography 
Affinity columns were prepared by coupling MAb 5E4 or MAb 4G10 (free PSA-
specific antibody) to CNBr-activated Sepharose (Amersham Pharmacia Biotech). 
After the application of the samples, the column was washed with 50 mmol/L 
Tris-HCl containing 0.5 mol/L NaCl. PSA was eluted with 0.1% trifluoroacetic 
acid (TFA) in water, and neutralized with 1 mol/L Tris base. 
6.8.5. Peptide affinity chromatography
Peptides B-2 and C-4 with a spacer sequence were coupled to an activated CH-
Sepharose gel (Amersham Pharmacia Biotech). After incubation at 4oC for 12 h, 
the remaining active groups were blocked by adding 0.1 M Tris-HCl, pH 8, for 1 
h. The peptide affinity column was equilibrated with 10 mmol/L Tris-HCl, pH 
7.8, or with the same buffer containing 100 µmol/L ZnCl2 (binding buffers). 
Partially purified (ammonium sulfate-precipitated), immunoaffinity-purified 
PSA, purified LNCaP-proPSA before and after trypsin activation, or PEG-
precipitated serum were dialyzed against binding buffer and applied to the 
peptide affinity column at a flow rate of 0.5 mL/min. After washing with 15-25 
bed volumes of 10 mmol/L Tris-HCL, bound PSA was eluted with 10 mmol/L 
acetic acid.
6.9. Electrophoresis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed under reducing and nonreducing conditions on homogeneous 15% or 
20% polyacrylamide gels with the PhastSystem (Amersham Pharmacia Biotech). 
Isoelectric focusing (IEF) was performed with the PhastSystem (Amersham 
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Pharmacia Biotech) using a gel with the pH range 5-8. Proteins separated by 
SDS-PAGE and IEF were detected by silver staining according to the instructions 
of the manufacturer. 
6.10. Surface plasmon resonance 
The binding kinetics of selected peptides to PSA was studied by surface plasmon 
resonance (166, 167) on a BIAcore 2000™ instrument (Biacore AB, Uppsala, 
Sweden). PSA was immobilized to the solid phase by MAb H117, which binds to 
the same epitope as MAb 5E4 (168, 169). The capture antibody was covalently 
coupled onto the surface of the CM5 sensor chip. PSA in PBS was injected for 4 
min at a flow rate of 5 µL/min. After washing, peptides as GST fusion proteins 
were injected at various concentrations for 1 min at a flow rate of 20 µL/min. To 
characterize the effect of Zn2+ on the affinity of the peptides, the sensorgrams 
were recorded for a constant amount of peptide in the presence of Zn2+ (0-30 
µmol/L) both in the running and sample buffer. PSA-binding to either chemically 
activated/deactivated blank surface or MAb H117 alone was subtracted as a 
nonspecific interaction. Regeneration after each measurement cycle was done 
with 3 x 0.5 min injections of 10 mmol/L HCl. Binding data were analyzed using 
BIAEVALUATION software (Biacore AB). 
6.11. Nuclear magnetic resonance (NMR) method 
The peptides were dissolved in DMSO-d6. All spectra were recorded at 300-320 
K on a Bruker Avance 500 NMR spectrometer (Bruker, Germany) operating at a 
frequency of 500 MHz. All 1-D experiments were recorded at five different 
temperatures over the range 300-320K. The temperature coefficients (?????) of the 
amide protons were calculated by analyzing the chemical shifts at these five 
temperatures. Two-dimensional experiments were performed at 305 K or 310 K 
depending on the quality and clarity of the spectra.
 The structure of the peptides is analyzed by using DYANA software (170).
The final DYANA structures were modeled and visualized with the software 
package QUANTA using the CHARMM program running on a Silicon Graphics 
workstation (171).
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7. RESULTS 
7.1. Identification of PSA-binding peptides (I)
1) PSA-binding peptides 
We selected 14 peptide sequences from four different phage display peptide 
libraries. The peptides isolated from each library contained characteristic 
consensus amino acids in addition to the cysteines engineered in fixed positions 
(Table 4).
Table 4. Amino acid sequences of PSA-binding peptides. 
Code Origination
  library 
Peptide sequence No. of
isolates
A-1*
A-2
 CX8C
 CX8C
C V F T S D Y A F C
C V I Y D G N H W C 
2
2
A-3  CX8C C I F E P D Y S Y C 2
A-4  CX8C C V F D D L Y S F C 1
B-1  CX10C C T F S V D Y K Y L M C 15
B-2*  CX10C C V F A H N Y D Y L V C 2
B-3  CX10C C R F D K E Y R T L V C 1
C-1  CX3CX4CX2C C V S Y C L F E F C Y V C 2
C-2  CX3CX4CX2C C V E Y C W E G S C Y V C 7
C-3  CX3CX4CX2C C V A Y C E E W E C Y V C 1
C-4*  CX3CX4CX2C C V A Y C I E H H C W T C 3
C-5  CX3CX4CX2C C V S Y C D G L Q C W M C 1
D-1*  CX3CX3CX3C C L S T C A Q S C R I S C 7
D-2  CX3CX3CX3C C L L Y C H D A C W W V C 2
Single-stranded DNA was purified from phage clones after three rounds of selection 
with PSA. Peptide sequences were deduced from the DNA sequences of the 
corresponding region of the phage genome. Consensus residues found in several clones 
are indicated in boldface. Peptides produced as glutathione S-transferase (GST) fusion 
proteins are indicated with an asterisk. 
Four PSA-binding peptides displaying the strongest binding were 
constructed as GST fusion proteins. Peptide C-4 with the sequence 
CVAYCIEHHCWTC showed the strongest binding to PSA both as a GST-peptide 
(Fig. 6) and when expressed on a phage. Two other selected peptides, B-2 
(CVFAHNYDYLVC) and A-1 (CVFTSDYAFC), bound to PSA but less efficiently 
than C-4. The fourth peptide (D-1) produced as a GST fusion protein did not 
show significant binding to PSA even as the corresponding phage clone bound to 
PSA.
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Fig. 6. Binding of GST-peptides to immobilized PSA. 
Various amounts of each GST-peptide were added to wells containing PSA captured by 
MAb 5E4. The binding of GST-peptides was quantified by IPMA. Data represent mean
values from duplicate wells ± standard errors (SE). 
The gel filtration of GST-C-4 revealed four peaks (Table 5, Fig. 7). The 
molecular sizes of the peaks were > 500 kDa, 100 kDa, 30 kDa, and about 3 kDa. 
All of these except the 3-kDa peak bound to PSA in IPMA (Table 5, Fig. 7). This 
indicates that the GST-peptide exists as a 30-kDa monomer, an oligomer (about 
100 kDa), and a polymer. The polymeric GST-peptide showed the strongest 
binding to PSA, as indicated by the response in relation to the protein absorbance 
at 280 nm. The GST fusion protein contains the thrombin recognition sequence 
and can be cleaved with thrombin. Thrombin treatment of GST-C-4 caused 
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nearly complete cleavage into 30-kDa (GST only) and 3-kDa components. The 3-
kDa components consisted of the estimated 31-residue long peptide cleaved from 
the GST-peptide by thrombin. The 30-kDa component retained about 5% of the 
response in the GST-peptide IFMA in comparison with the noncleaved GST-C-4 
(Table 5). In inhibition experiments, the 3-kDa peak reduced the binding of GST-
peptide to PSA by about 30% (Fig. 7).
Table 5. Comparison of the activities of different molecular size forms of GST-C-4. 
Fusion protein RMM
(kDa)
Protein
(% of total) 
Binding activity 
   (% of total) 
GST-C-4     ~ 3   3.4        ND 
  ~ 30 83.4        53 
~ 100 11.4        26 
> 500   1.7        21 
Thrombin-     ~ 3 17        ND 
cleaved   ~ 30 83          5.2* 
GST-C-4
In gel filtration, GST-C-4 and thrombin-cleaved GST-C-4 revealed four and two peaks, 
respectively. The percentage of protein in each peak was estimated by absorbance at 280 
nm. The binding activity was calculated from the IPMA assay.
RMM, relative molecular mass. ND, Cannot be detected. *Denotes binding activity 
remaining after thrombin treatment. 
2) Properties and specificity of PSA-binding peptides   
To determine the binding site of the peptides on PSA, inhibition experiments 
were performed with MAbs binding to various epitopes on PSA. Antibodies 
binding to epitope regions, which in complexed PSA are covered by the serpin 
?1?antichymotrypsin (ACT) (also called free-specific antibodies), inhibited the 
binding of the peptides most strongly (>80%). MAbs binding to epitopes distant 
from the active site of PSA showed a lower degree of inhibition (Table 6). 
 The binding of GST-peptide fusion proteins (B-2 and C-4) to PSA was blocked 
in a dose-dependent fashion by the corresponding synthetic peptide (Table 7). 
No significant difference was present in reactivity between peptides with and 
without a spacer. 
 When Zn2+, a cation known to bind to PSA, was included in the assay buffer, 
the binding activity of peptides was increased. Zn2+ had a dose-dependent effect 
and the maximal increase in binding response was at a concentration of 200 
µmol/L.
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Fig. 7. Fractionation of the GST-C-4 by gel filtration.
After fractionation of GST-C-4 or thrombin-treated GST-C-4, 5 µL of each fraction was
first incubated in wells containing PSA bound by MAb 5E4. The binding was measured 
by IPMA. The arrows show the elution of molecular size standards (669 kDa, 150 kDa,
43 kDa, and 1.3 kDa). The cross symbol (x) shows the inhibition of the binding of GST-
peptide induced by the peptide cleaved from GST-peptide. For this test, 200 µL of each
fraction containing free peptide was first incubated in wells containing PSA captured by 
MAb 5E4. After 1 h, the wells were emptied and GST-C-4 (167 nmol/L) was added. After
incubation for 1 h, the binding of GST-peptide was measured by IPMA. Data represent
mean values from duplicate wells. 
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Table 6. Inhibition of GST-peptide binding to PSA by PSA-MAbs. 
ISOBM-MAb  Epitope   GST-peptide 
   group 
Code (name) A-1 B-2 C-4
25 (5A10) 
26 (9B10) 
40 (2E9) 
       1 
       1 
       2-a 
++
++
 + 
++
++
 + 
++
++
 + 
90 (41R5)        2-b  +  +  + 
57 (H50)        3-a  +  +  + 
89 (109R75)        3-b  +  +  + 
86 (PSM773)        5  +  +  + 
Control        6  -  -  - 
PSA-MAbs representing four epitope groups on PSA were used to compete with the 
GST-peptides for binding to PSA. An antibody from group 6, in which MAb 5E4 
belongs, was used as a negative control. Each MAb (33.3 nM) was incubated with PSA 
captured by 5E4 coated onto microtitration wells. After washing, GST-peptide was 
added. The binding of GST-peptides was quantified by fluorometry. 
Reduction of binding of GST-peptide to solid-phase PSA (%) 
++ =  > 80% 
 +  = 60-80% 
 -  = No inhibition 
Table 7. Effect of synthetic peptides with and without a spacer on the binding of 
GST-peptides to immobilized PSA.
Inhibition by synthetic peptide (%) 
Concentration B-2 B-2 linker C-4 C-4 linker 
1.7 µM 39 40 41 31
17 µM 71 72 81 70
34 µM 75 78 90 80
Various amounts of synthetic peptides and the corresponding GST-peptide (0.17 µM) 
were added to wells containing PSA bound by MAb 5E4. The binding of GST-peptides 
was quantified by fluorometry.  



When analyzed by isoelectric focusing, the main form of peptide-bound PSA
was PSA-B (pI 6.9), while PSA-A (pI 7.2) formed only a faint band (Fig. 4 in the 
original publication II). Unbound PSA also displayed a major band at pI 6.9 
(corresponding to PSA-B, -C and -D) and a faint band at pI 6.7 (PSA-E) (Fig. 4 in 
the original publication II). When PSA isoenzymes A, B, C, D, and E purified by 
anion exchange chromatography were fractionated on the peptide column, about 
70% of “intact” isoenzymes A and B bound to the column, as compared with 25% 
of PSA C, 12% of PSA-D, and 7% of PSA-E. 
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Fig. 10. Effect of GST-C-4 on the enzymatic activity of PSA. 
PSA (0.33 µM) was incubated with increasing concentrations of GST-C-4 (0 to 100-fold 
molar excess) for 1 h, after which the chromogenic substrate S-2586 was added and 
enzymatic activity was monitored by measuring the absorbance at 405 nm. Data
represent mean values from duplicate wells ± SE.
The enzymatic activity of PSA separated with the peptide column was
analyzed by reacting bound and unbound forms with ACT. After 24 h, about 77% 
of peptide-bound PSA and 30% of unbound PSA had formed a complex. The 
reactivity of peptide-bound PSA was similar to that of PSA isoenzyme B, and that 
of unbound PSA was similar to that of PSA isoenzyme C. 
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between residues Ala-4 and Tyr-7 for B-2, and a type II ?-turn between Ile-6 and 
His-9 for C-4. However, the most important stabilizing effect for the peptide 
structures was the disulfide bridge between the N- and C-terminal cysteines, 
peptide C-4 having an additional disulfide bond between Cys-5 and Cys-10, 
enabling a tight turn in the sequence between these amino acids.
The effect of peptides and alanine replacement derivatives on the enzymatic 
activity of PSA, showed that most of the changes caused inactivation or 
reduction of the enzyme activating capacity on PSA. However, replacement of 
His-5 by Ala-5 in B-2 increased the activity. In peptide C-4, the effect was 
strongly decreased when Tyr-4, Ile-6, and Try-11 were replaced by alanine. 
Analysis of the binding specificity of peptides on PSA by a cross-inhibition 
experiment showed that binding of GST fusion protein C-4 to PSA was blocked 
by each of the synthetic peptides A-1, B-2, and C-4 in a dose-dependent fashion 
(Fig. 4 in the original publication IV). At a 100-fold molar excess of the synthetic 
peptides, the inhibition was between 60% and 70%.  This suggests that the 
peptides bind to the same site on PSA.
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8. DISCUSSION
8.1. Identification and characteristics of novel PSA-binding ligands 
PSA is a serine protease and a sensitive serum marker for PCa. Measurement of 
serum PSA is widely used for early detection and management of PCa patients. 
However, false-positive results caused by BPH limit the utility of the PSA assay 
for diagnosis of PCa. Measurement of the proportions of free PSA and the PSA-
ACT complex has been used to reduce the number of false-positive results by 20-
30% (172, 173).  However, even with this approach, the frequency of false- 
positive results is over 50%. Recent studies suggest that detection of variants of 
free PSA could improve discrimination between PCa and BPH (14, 15). We 
therefore aimed at identifying specific ligands for cancer-related forms of PSA.
 Phage libraries can display 109 different peptides on the surface of phage. The 
peptides are expressed as a fusion with phage surface proteins. We initially 
coated PSA directly onto microtitration wells, but with this method no PSA-
binding phage could be isolated. Apparently, direct immobilization of PSA onto 
the wall of the microtitration well ether changes the PSA structure or causes it to 
adopt an unfavorable orientation for biopanning. We changed the strategy by 
using a MAb, which does not block the active site, to capture PSA. With this 
approach, 14 PSA-binding peptides were identified. We have screened several 
linear phage display peptide libraries, but no peptides were isolated. From each 
cyclic phage peptide library, by contrast, several sequences could be identified. 
This strongly suggests that the essential structure of the peptide-libraries is 
important and a cyclic conformation is necessary for binding and is more stable 
for the interaction with PSA. Among the selected peptides, bicyclic peptides 
(with four cysteines) showed the highest affinity. Phage fUSE5 expresses 3-5 
copies of the pIII protein fused to peptide inserts containing the same sequence, 
resulting in multivalent binding (174).
 To facilitate studies on the binding properties and specificity of the peptides, 
they were produced as GST-peptide fusion proteins. These fusion proteins 
contained three molecular size forms: monomer, oligomer and polymer. The 
polymer displayed the strongest binding to PSA, followed by the oligomer and 
the monomer, this indicates that multivalent binding enhances binding avidity.
 In the presence of Zn2+, the affinity constants of the GST-peptides increased 3- 
to 7-fold, suggesting involvement of Zn2+ in the binding between PSA and 
peptides. Surface plasmon resonance (BIA core) experiments showed that the 
effect of Zn2+ was explained by a decrease in dissociation rate rather than an 
increase in association rate. This may be mediated by Zn2+ chelated between 
amino acid residues of PSA and the peptide or by altering the structure of PSA. 
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Interestingly, zinc inhibits the enzymatic activity of PSA (17, 175). Another 
possibility is that Zn2+ stabilizes the 3-D structure of the peptide in a way similar 
to the interaction of Zn2+ with DNA-binding zinc finger proteins (176, 177).
 The peptides did not bind to chymotrypsin and cathepsin G, which have an 
enzymatic specificity similar to that of PSA. Neither did they bind to hK2, which 
is structurally closely related to PSA and shows 79% identity at the amino acid 
level (76). In addition, The GST-peptides did not bind to PSA-serpin complexes 
occurring in serum, i.e. PSA-ACT and PSA-API, in which the serpins cover the 
peptide-binding region on PSA. The binding of peptides to PSA was also blocked 
by antibodies that react with free PSA through epitopes covered in PSA-serpin 
complexes; moreover, these MAbs inhibit the enzymatic activity of PSA (168).
Thus, the peptides are specific to enzymatically active free PSA. The peptides 
enhanced the enzymatic activity of PSA against the synthetic peptide substrate S-
2586, and the effect correlated with the affinity of the peptides to PSA. These 
results suggest that the peptides bind to the vicinity of the active site, changing 
the conformation of PSA, which possibly makes the catalytic pocket more 
accessible to synthetic substrates. 
8.2. Conformational and biochemical analyses of PSA-binding 
peptides
PSA-binding peptides (A-1, B-2, and C-4) contain the aromatic amino acid 
tyrosine. The other consensus amino acids, phenylalanine, valine, and leucine, 
have hydrophobic side-chains. Replacement of the key amino acid tyrosine with 
alanine caused total loss of binding to PSA. Replacement of alanine for other 
consensus amino acids also reduced the binding activity. These findings suggest 
that amino acids containing aromatic or hydrophobic side-chains are the contact 
residues with PSA, and they are responsible for the binding and spatial 
arrangement between the peptide and PSA. Replacement of nonconsensus amino 
acids with alanine did not cause loss of binding to PSA. Thus, other amino acids, 
as elements of the peptide backbone, play a role in the conformation of peptides 
but are not essential for binding. 
 NMR analysis suggested that peptide cyclization was induced in turn 
conformations, which are essential for the effect on the enzymatic activity of 
PSA. Apparently, the turn structures of the peptides place the binding residues 
in an exposed conformation for interaction with PSA.
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8.3. Separation of enzymatically active and inactive PSA by peptide 
affinity chromatography 
The peptides were verified by synthesizing them chemically and preparing an 
affinity column linking the peptide through a spacer to the matrix. The spacer 
does not affect the function of the peptides but preserves their activity after 
immobilization. When PSA comprising various forms was fractionated by 
peptide affinity chromatography, the intact, enzymatically active PSA was 
retained and could be isolated. ProPSA, which is enzymatically inactive, did not 
bind to the peptide, but after activation by trypsin about 56% bound to the 
peptide column. When serum samples from PCa patients were applied to the 
column, a minor fraction of free PSA bound to the column, suggesting that some 
enzymatically active PSA remains free in circulation. These studies demonstrate 
that the PSA-binding peptides have unique specificity and recognize 
enzymatically active free PSA.  
8.4. Immunopeptidometric assay for enzymatically active PSA 
Reagents specifically recognizing the active form of PSA are potentially useful for 
PCa diagnostics, but antibodies specific to active PSA are not available. 
Antibodies bind to epitopes on the surface of PSA (168) and do not recognize 
structural differences within grooves and pits of the protein. Short cyclic 
peptides containing 10-13 amino acids apparently have the ability to recognize 
differences in the inner structure of PSA.
 In PCa, the normal structure of the prostate is deranged by disruption of the 
basal cell layer and basement membrane. PSA may therefore directly be released 
into the extracellular space and reach the circulation. This could explain the high 
proportion of PSA complexed with inhibitors in PCa patients (61).  When 
enzymatically active PSA purified from seminal fluid is added to serum, most of 
it binds to A2M and ACT, but a small portion remains free. Our finding of active 
PSA in patient samples indicates that the reaction between PSA and inhibitors 
leaves part of the active PSA free.
The IPMA is a new assay principle based on the use of peptides as a tracer in 
combination with a monoclonal capture antibody. All forms of PSA were 
captured by the immobilized MAb, but only enzymatically active free PSA was 
recognized by the peptide. By using an immunofluorescent enzymatic assay, 
Niemelä et al. found that about 3% enzymatically active free PSA occurs in serum 
of PCa patients (13). Our finding is in line with this result. The IPMA, thus, offers 
a potential approach for detection of cancer-associated forms of PSA. However, 
the sensitivity of the IPMA needs to be improved in order to detect active PSA at 
clinically important concentrations, i.e. 3-10 µg/L. 
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9. SUMMARY 
PSA, as the most important marker, is widely being used for diagnosis and 
monitoring of PCa, but the high frequency of false-positive results is problematic. 
The purpose of this study was to identify novel PSA-binding peptides that can be 
utilized as reagents for development of more cancer-specific diagnostic methods 
and as tools for targeting PCa. 
 First, a new strategy for selection of phage-displayed peptides was 
developed. By using a monoclonal PSA antibody, which does not block the active 
site of the enzyme, PSA was immobilized on microtitration wells. Fourteen PSA-
binding peptides were selected from four cyclic phage libraries. To facilitate 
studies on the binding properties and specificity of the peptides, representative 
peptides from each phage library were produced as GST fusion proteins and also 
synthesized chemically. Bicyclic peptide C-4 (with four cysteines) showed the 
highest binding affinity to PSA. The peptides did not bind to other serine 
proteinases or to PSA-serpin complexes occurring in serum. The peptides 
enhanced the enzymatic activity of PSA. These results suggest that the peptides 
bind to the vicinity of the active site, changing the conformation of PSA. 
 The conformation of PSA-binding peptides was analyzed by NMR, and the 
effect of alanine replacement derivatives on the enzymatic activity of PSA was 
studied. The results suggest that the effect of the peptides on PSA enzymatic 
activity is based on the interaction with aromatic and hydrophobic side-chains of 
amino acids in the PSA-binding peptides. The cysteine disulfide bond of the 
peptides plays an important role in stabilizing the peptide structure. 
 A peptide affinity column was prepared by linking the peptide through a 
spacer to the Sepharose gel. Intact, enzymatically active free PSA was bound to 
the peptide affinity column, whereas internally cleaved forms and proPSA were 
not. When serum from PCa patients was applied to the peptide column, a minor 
fraction of free PSA could be separated from other forms of PSA.
 An immunopeptidometric assay (IPMA) for enzymatically active PSA was 
developed. All forms of PSA were captured by a PSA-MAb onto the solid phase, 
and a peptide fusion protein to PSA was used as a tracer to quantitate the 
enzymatically active PSA. The IPMA detected enzymatically active PSA purified 
from seminal fluid and proPSA from LNCaP cell culture medium after activation 
by trypsin. The minor fraction of free PSA in serum of PCa patients was 
recognized by the IPMA. Thus, this new assay principle has wide potential 
utility.
 In conclusion, PSA-binding peptides with unique specificity were identified 
by phage display. These peptides, containing 10-13 amino acids, have the ability 
to recognize the inner structure of PSA and may be able to diffuse into tissues 
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and target PSA-secreting cells. These peptides are thus promising tools for the 
development of novel diagnostic methods and targeted therapeutics for PCa. 
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